From: Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study
Organ system | Total | ATII | Placebo | P-value |
---|---|---|---|---|
Metabolic disorders | 16 | 11 | 5 | |
Acidosis | 2 | 3 | 1.00 | |
Alkalosis | 4 | 0 | 0.09 | |
Blood or lymphatic disorders | 7 | 3 | 4 | 1.00 |
Respiratory disorders | 6 | 3 | 3 | 1.00 |
Worsening respiratory failure | 1 | 3 | 0.58 | |
Wheezing | 1 | 0 | 1.00 | |
Cardiac disorders | 12 | 7 | 5 | 0.65 |
Hypertension1 | 2 | 0 | 0.58 | |
Hypotension | 2 | 1 | 1.00 | |
Atrial fibrillation | 2 | 0 | 0.47 | |
Renal disorders2 | 7 | 6 | 2 | 0.17 |
Decreased urine output | 3 | 1 | 0.58 | |
Worsening acute kidney injury | 0 | 2 | 0.47 | |
Other disorders3 | 8 | 5 | 3 | 0.65 |
Worsening multiple organ system failure | 2 | 3 | 1.00 |